Vifor Pharma Ag Stock Price To Earning
| GNHAYDelisted Stock | USD 38.39 0.00 0.00% |
Vifor Pharma AG fundamentals help investors to digest information that contributes to Vifor Pharma's financial success or failures. It also enables traders to predict the movement of Vifor Pink Sheet. The fundamental analysis module provides a way to measure Vifor Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vifor Pharma pink sheet.
Vifor |
Vifor Pharma AG Company Price To Earning Analysis
Vifor Pharma's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Vifor Pharma Price To Earning | 30.39 X |
Most of Vifor Pharma's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vifor Pharma AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Vifor Pharma AG has a Price To Earning of 30.39 times. This is 17.61% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to earning for all United States stocks is 5.81% lower than that of the firm.
Vifor Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vifor Pharma's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Vifor Pharma could also be used in its relative valuation, which is a method of valuing Vifor Pharma by comparing valuation metrics of similar companies.Vifor Pharma is currently under evaluation in price to earning category among its peers.
Vifor Fundamentals
| Return On Equity | 0.0665 | |||
| Return On Asset | 0.0458 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 10.99 B | |||
| Shares Outstanding | 324.46 M | |||
| Price To Earning | 30.39 X | |||
| Price To Book | 3.22 X | |||
| Price To Sales | 6.39 X | |||
| Revenue | 1.82 B | |||
| Gross Profit | 1.14 B | |||
| EBITDA | 519.6 M | |||
| Net Income | 144.4 M | |||
| Cash And Equivalents | 993.6 M | |||
| Cash Per Share | 3.06 X | |||
| Total Debt | 75 M | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 1.91 X | |||
| Book Value Per Share | 10.76 X | |||
| Cash Flow From Operations | 527.4 M | |||
| Earnings Per Share | 0.49 X | |||
| Number Of Employees | 2.2 K | |||
| Beta | 1.03 | |||
| Market Capitalization | 12.45 B | |||
| Total Asset | 5.1 B | |||
| Retained Earnings | 2.01 B | |||
| Working Capital | 567 M | |||
| Current Asset | 1.29 B | |||
| Current Liabilities | 726 M | |||
| Z Score | 99.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 5.1 B | |||
| Last Dividend Paid | 2.0 |
About Vifor Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vifor Pharma AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vifor Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vifor Pharma AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |